Merck Millipore Introduces New Excipient for Solubility/Bioavailability Enhancement - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck Millipore Introduces New Excipient for Solubility/Bioavailability Enhancement


Merck Millipore, the life-science division of Merck, has developed a new solubility/bioavailability enhancement excipient, Parteck SLC, which has a unique pore structure that enables higher loading of amorphous APIs, thereby, improving dissolution rates and increasing drug solubility.

Parteck SLC’s mesopores (2–7 nm) create a surface area of up to 1000 m2/g for depositing an API in its amorphous form needed for supersaturation. The internal surface area of Parteck SLC is also easily accessible and the API is kept stable. A user-friendly particle size (5–25 μm) and bulk density (0.32 g/ml) allow easy loading, tableting, or capsule creation.

Parteck SLC is not a novel excipient. Regulatory requirements, therefore, remain the same as it conforms to the silica monographs of Ph Eur and USP. Parteck SLC comes with ready-to-use documentation in CTD-format. Feasibility studies on loading and in vitro dissolution are also available.

Matthias Bucerius, PhD, head of pharmaceutical raw materials, commented in a press statement, that many promising drug candidates fail to get pass the development hurdle because of poor bioavailability and this problem causes significant loss of time and resources to companies. The addition of Parteck SLC to Merck Millipore’s portfolio of excipients provides drug developers with a new option to increase the solubility/bioavailability of their APIs or reformulate their drugs to extend product lifecycle.

Source: Merck Millipore

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here